Zentalis has been progressing with azenosertib through multiple programs. This includes monotherapy studies such as ZN-c3-001 and DENALI Part 1b, as well as in combination with niraparib in the ...

Zentalis reports updated DENALI trial results for azenosertib in platinum-resistant ovarian cancer, showing 6.3 months median duration of response. Updated median duration of response (mDOR) of 6. ...

It’s one step backward in order to take two steps forward at Zentalis Pharmaceuticals Inc. In a restructuring to help fund the second part of its potentially registration-enabling Denali study, ...

Explore Zentalis Pharma stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ZNTL. FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies ...

In this article, we are going to take a look at where Zentalis Pharmaceuticals (NASDAQ:ZNTL) stands against other cheapest stocks that insiders are buying recently. Why should we be interested in ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th.

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals ... MAMMOTH is a multi-arm study that evaluated azenosertib monotherapy and in combination with niraparib in patients with ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...